UBS Starts Vertex (VRTX) at Neutral; Near-Term Bias
Tweet Send to a FriendGet Alerts VRTX Hot Sheet
Price: $79.49 +2.05%
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
17 Buy, 11 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade VRTX Now!
UBS initiates coverage on Vertex (NASDAQ: VRTX) with a Neutral. PT $56.
UBS analyst says, "Vertex is poised to lead a new era of hepatitis-C virus (HCV) antivirals with the recent FDA approval of Incivek, which we and the Street view as a potential blockbuster opportunity. Further, the HCV program is complemented by a novel and potentially transformative cystic fibrosis (CF) program, which we believe may address the vast majority of CF patients. We are initiating coverage of Vertex with a Neutral rating despite a near-term and long-term positive stance, given valuation, our view that upside to 2012-14 Incivek sales could be limited, and the longer timelines to key VX-809 data."
For more ratings news on Vertex click here and for the rating history of Vertex click here.
Shares of Vertex closed at $50.17 yesterday, with a 52 week range of $31.86-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
UBS analyst says, "Vertex is poised to lead a new era of hepatitis-C virus (HCV) antivirals with the recent FDA approval of Incivek, which we and the Street view as a potential blockbuster opportunity. Further, the HCV program is complemented by a novel and potentially transformative cystic fibrosis (CF) program, which we believe may address the vast majority of CF patients. We are initiating coverage of Vertex with a Neutral rating despite a near-term and long-term positive stance, given valuation, our view that upside to 2012-14 Incivek sales could be limited, and the longer timelines to key VX-809 data."
For more ratings news on Vertex click here and for the rating history of Vertex click here.
Shares of Vertex closed at $50.17 yesterday, with a 52 week range of $31.86-$58.87.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Vertex Calls for Redemption of $400 Million in Convertible Senior Subordinated Notes Due 2015
- Wunderlich Securities Starts Vertex Energy (VTNR) at Buy
- BTIG Starts Ambac Financial (AMBC) at Buy, Interesting Play with 'Optionality'
Create E-mail Alert Related Categories
New CoverageRelated Entities
UBS
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
